2013
Pathology Consultation on Evaluating Prognosis in Incidental Monoclonal Lymphocytosis and Chronic Lymphocytic Leukemia
Siddon AJ, Rinder HM. Pathology Consultation on Evaluating Prognosis in Incidental Monoclonal Lymphocytosis and Chronic Lymphocytic Leukemia. American Journal Of Clinical Pathology 2013, 139: 708-712. PMID: 23690112, DOI: 10.1309/ajcplir4gzwx3xka.Peer-Reviewed Original ResearchMeSH KeywordsADP-ribosyl Cyclase 1Beta 2-MicroglobulinFlow CytometryGene Rearrangement, B-LymphocyteHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionIncidental FindingsLeukemia, Lymphocytic, Chronic, B-CellLymphocytosisMaleMiddle AgedMutationPrognosisWatchful WaitingZAP-70 Protein-Tyrosine KinaseConceptsChronic lymphocytic leukemiaEarly-stage chronic lymphocytic leukemiaStage chronic lymphocytic leukemiaDisease progressionLymphocytic leukemiaImmunoglobulin heavy chain variable (IGHV) gene mutational statusMonoclonal B-cell lymphoproliferative disorderLaboratory evaluationOvert chronic lymphocytic leukemiaMonoclonal B-cell lymphocytosisB-cell lymphoproliferative disordersAggressive disease progressionSignificant disease progressionIndolent clinical courseSerum β2-microglobulinRoutine laboratory evaluationB-cell lymphocytosisZAP-70 expressionGene mutational statusMonoclonal lymphocytosisClinical courseExpectant observationLymphoproliferative disordersTherapeutic optionsPrognostic marker
1997
Acquired von Willebrand's disease: A concise review
Rinder M, Richard R, Rinder H. Acquired von Willebrand's disease: A concise review. American Journal Of Hematology 1997, 54: 139-145. PMID: 9034288, DOI: 10.1002/(sici)1096-8652(199702)54:2<139::aid-ajh7>3.0.co;2-y.Peer-Reviewed Original ResearchConceptsVon Willebrand factorHigh molecular weight multimersMonoclonal gammopathyAcquired von Willebrand diseaseEmergent cardiac surgeryUnderlying lymphoproliferative disorderLower functional levelUnderlying lymphoproliferative diseaseVon Willebrand diseaseIntravenous immunoglobulinCardiac surgeryLymphoproliferative disordersFactor inhibitorsAutoimmune diseasesLymphoproliferative diseaseUnderlying disorderEffective therapyBleeding diathesisIllustrative case historiesAvWDTherapeutic strategiesAntigenic levelsWillebrand diseaseReticuloendothelial systemTumor cells